Nebivolol Amarox

Nebivolol, the active ingredient in Nebivolol Amarox, is a beta blocker presented as an oral tablet for oral use. It is employed to lower high blood pressure and to improve outcomes in patients with heart failure, in adult patients, and is approved in the European Union.

GNH USA supplies Nebivolol Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. Our distribution network reaches over 50 countries.

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management.

Hypertension: reduces systolic and diastolic blood pressure, decreasing risk of stroke and myocardial infarction. Heart failure: improves left ventricular ejection fraction and relieves symptoms in patients with reduced‑ejection‑fraction heart failure. Chronic heart failure (NYHA class II‑III): decreases hospitalizations and mortality in this patient group.

Nebivolol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Dizziness - Fatigue - Bradycardia - Nausea - Peripheral edema

Serious or Rare Side Effects: - Severe bradycardia or heart block - Bronchospasm, especially in patients with reactive airway disease - Allergic reactions including anaphylaxis - Hepatic dysfunction or elevated liver enzymes

When prescribing nebivolol, clinicians should consider several precautionary measures to ensure patient safety.

Monitor blood pressure: check regularly to assess therapeutic response. Assess heart rate: watch for excessive bradycardia, especially in patients with conduction disorders. Use caution in asthma or chronic obstructive pulmonary disease: beta‑blockade may precipitate bronchospasm. Avoid abrupt discontinuation: taper dose to prevent rebound hypertension. Adjust dose in renal impairment: consider reduced dosing in patients with decreased renal function. Store at room temperature: keep in the original container, protect from moisture.

Nebivolol can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective beta blockers: concurrent use may cause excessive β‑blockade. - Calcium channel blockers (verapamil, diltiazem): increase nebivolol plasma levels. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): may raise nebivolol concentrations.

Moderate Interactions (Monitor Closely): - Other antihypertensives (ACE inhibitors, ARBs): additive blood pressure lowering. - Diuretics: may enhance hypotensive effect. - Insulin or oral hypoglycemics: nebivolol can mask hypoglycemia symptoms.